BioNTech SE (NASDAQ:BNTX) Receives $138.64 Average Target Price from Analysts

BioNTech SE (NASDAQ:BNTX) has earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $138.67.

Several research firms have recently weighed in on BNTX. HSBC lifted their target price on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. TD Cowen decreased their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft raised their price objective on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, September 19th. Finally, The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $90.00 to $137.00 in a research note on Friday, November 8th.

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baillie Gifford & Co. increased its position in shares of BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares during the last quarter. FMR LLC raised its stake in shares of BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after acquiring an additional 5,598,190 shares during the period. Deerfield Management Company L.P. Series C lifted its holdings in shares of BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after acquiring an additional 24,426 shares during the last quarter. Candriam S.C.A. boosted its position in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Finally, Fred Alger Management LLC acquired a new stake in BioNTech in the 3rd quarter valued at approximately $59,485,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

NASDAQ BNTX opened at $115.59 on Wednesday. The company has a market cap of $27.71 billion, a price-to-earnings ratio of -55.04 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock’s fifty day moving average price is $113.89 and its 200 day moving average price is $98.94. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.73 earnings per share. As a group, equities research analysts forecast that BioNTech will post -3.72 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.